The smoking cessation methods that actually work

Quitting smoking alone, without any help, remains very difficult: only 3 to 5% of unaided attempts are still successful a year later. This figure says nothing about the willpower of the people involved. It reflects the strength of nicotine dependence. The good news is that far more effective methods exist, that they are accessible, and that they can be combined.

Many attempts, little help used

In France, more than half of daily smokers (55%) want to quit, and 17.3% tried to for at least a week in 2024, according to Santé publique France. In the United States, the CDC reports that 53% of adult smokers tried to quit during a given year, but only 8.8% succeeded. Among those who tried, fewer than four in ten had used support or medication. Worldwide, the World Health Organization (WHO) notes that support combined with treatment more than doubles the chances of success.

The gap between the number of attempts and the number of successes is therefore largely explained by the fact that many people try on their own.

Support, the key factor

The French National Authority for Health (HAS) is clear on this point: support from a healthcare professional is one of the decisive factors in success. This can be a primary care doctor, a tobacco cessation specialist, a pharmacist, a nurse, or a midwife. Weekly follow-up at the start, then monthly for three to six months, makes it possible to adjust the strategy and prevent relapse.

This support isn't limited to prescribing. It helps identify the situations that trigger the urge to smoke, prepare responses for those moments, choose a quit date, and get through the first few weeks. Cognitive behavioral therapy (CBT), focused on the habits and thoughts associated with smoking, has shown its effectiveness, alone or combined with treatment. Even brief advice from a doctor increases the chances of quitting.

Nicotine replacement therapy, as first-line treatment

Nicotine replacement treatments are recommended as first-line treatment by the HAS. They come in several forms: patches, gum, lozenges, tablets, inhalers, and mouth sprays. Their principle is to provide nicotine without the thousands of other toxic substances in smoke, to ease withdrawal while the body gradually breaks free of its dependence. Nicotine is not what causes cancer, nor most of tobacco's cardiovascular damage: that comes from the products of combustion.

Their effectiveness is well established. A Cochrane review covering more than 130 trials showed that nicotine replacement increases the chances of quitting by 50 to 60% compared with a placebo. Combining a patch, which releases nicotine throughout the day, with a fast-acting form used at moments of craving, is more effective than either form alone.

Two common mistakes reduce their effectiveness: too low a dose and stopping too early. An underdose lets withdrawal persist and leads to relapse. The dose is chosen based on the level of dependence, which a test such as the Fagerström test can help establish objectively, rather than guessing the right dose at random. Treatment generally lasts at least three months, with doses gradually tapered down.

In France, these products are reimbursed at 65% by national health insurance on prescription, with no annual cap, the rest usually covered by supplemental insurance. They can be prescribed by doctors, but also by midwives, nurses, dentists, and physiotherapists. In the United States, nicotine patches, gum, and lozenges are available over-the-counter, and many state quitlines provide them free of charge.

Medication, as second-line treatment

If well-conducted nicotine replacement therapy fails, two prescription medications may be offered.

Varenicline acts on the same brain receptors as nicotine. It reduces the urge to smoke and lessens the pleasure felt if someone smokes a cigarette again. In trials, it more than doubles the chances of quitting compared with a placebo. Treatment lasts twelve weeks. Withdrawn from the market in 2021 over an impurity issue, it has been available again in France since June 2025 and is reimbursed.

Bupropion is a medication from the antidepressant family that reduces the urge to smoke. It has more contraindications and is not reimbursed in France.

Past concerns about the neuropsychiatric safety of these medications were largely resolved by a major international trial, EAGLES, published in 2016 in The Lancet, involving more than 8,000 smokers. In France, they remain second-line treatments, to discuss with your doctor.

What about e-cigarettes?

The question is debated, and health authorities' positions aren't identical.

The effectiveness evidence has strengthened. The Cochrane review, updated through 2026, pools 90 studies and concludes, with high-certainty evidence, that nicotine e-cigarettes help more people quit than nicotine replacement therapy: out of 100 people, 8 to 10 quit with e-cigarettes, versus 6 with nicotine replacement. Serious adverse effects are rare.

Health authorities remain more cautious, for other reasons. The HAS and France's High Council for Public Health do not recommend it as a first-line cessation tool, citing insufficient long-term data. The WHO stresses that it isn't risk-free and is concerned about its use among young people. In the United States, the FDA has not approved e-cigarettes as a cessation aid, though some clinicians use them as a harm-reduction option for smokers who haven't succeeded with approved treatments.

In practice, if someone has already started vaping to quit smoking, that use shouldn't be discouraged. The benefit does, however, require quitting tobacco completely: continuing to smoke a few cigarettes alongside vaping keeps most of the risk. And e-cigarettes have no benefit at all for someone who doesn't smoke.

What hasn't been shown to work

Hypnosis, acupuncture, auriculotherapy, and laser treatment have not shown effectiveness beyond placebo in the available studies. The HAS doesn't recommend them, without banning them either: they pose no danger, provided they don't replace a form of help with proven effectiveness.

Free, accessible remote support

In France, Tabac Info Service offers free phone support at 39 89, Monday through Saturday, with follow-up from the same tobacco cessation specialist throughout the process. The service also offers a personalized program through a mobile app and its website. In the United States, the national quitline 1-800-QUIT-NOW offers similar free, confidential coaching and can connect you with your state's quit program.

Every November in France, the Mois sans tabac (“Smoke-Free Month”) campaign invites smokers to quit together for thirty days. This milestone matters: after a month without smoking, the chances of quitting for good are multiplied by five, according to Santé publique France.

Putting every chance on your side

A few pointers help in preparing to quit. Choose a date, rather than a vague “soon.” Tell people close to you. Identify risky moments in advance and plan what to do instead. Move more, which reduces cravings and limits weight gain. And don't treat a slip as a failure: most ex-smokers needed several attempts, and smoking one cigarette again doesn't doom the whole effort.

What to remember

There is no single “right” method. The most effective combination depends on the level of dependence and each person's situation. What clearly emerges from the research is that combining human support with suitable treatment markedly increases the chances of success compared with a solitary attempt.

To assess your own level of dependence, take the “Am I dependent on tobacco?” test.